University Medical Center Groningen
umcg.nlLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
619
Active
150
Phase 3
31
Total enrollment
422,770
Pipeline matrix
Showing 40 of 58 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| low dose tacrolimus in combination with everolimus | — | — | — | — | — | 1 | |
| standard dose tacrolimus with mycophenolate mofetil | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| Early discontinuation of Pembrolizumab with or without Bevacizumab | — | — | — | — | — | 1 | |
| Patiromer 8400 MG [Veltassa] | — | — | — | — | — | 1 | |
| Invokana 300 mg and 100 mg | — | — | — | — | — | 1 | |
| 18F-FDG | — | — | — | — | — | 1 | |
| Alectinib | — | — | — | — | — | 1 | |
| Leuprorelin | — | — | — | — | 2 | ||
| Finerenone | — | — | — | — | 2 | ||
| Hydrochlorothiazide 25 mg | — | — | — | — | — | 1 | |
| Dapagliflozin 10 mg/day | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 3 | ||
| cisplatin | — | — | — | — | 4 | ||
| Dexamethasone | — | — | 5 | ||||
| Dapagliflozin | — | — | — | — | — | 2 | |
| Cetrelimab | — | — | — | — | — | 1 | |
| ARI-0001 | — | — | — | — | — | 1 | |
| Axi-cel | — | — | — | — | — | 1 | |
| injection with 15 mg bevacizumab-800CW before bronchoscopy | — | — | — | — | — | 1 | |
| injection with 25 mg bevacizumab-800CW before bronchoscopy | — | — | — | — | — | 1 | |
| Medical Cannabis | — | — | — | — | — | 1 | |
| SC0062 strength 10mg | — | — | — | — | — | 1 | |
| SC0062 and dapagliflozin | — | — | — | — | — | 1 | |
| Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT | — | — | — | — | — | 1 | |
| Adalimumab-800CW | — | — | — | — | — | 1 | |
| 25mg adalimumab-680LT and 15/25 mg risankizumab-800CW | — | — | — | — | — | 1 | |
| Adalimumab-680LT 25mg | — | — | — | — | — | 1 | |
| Risankizumab-800CW 15 mg/25 mg | — | — | — | — | — | 1 | |
| Psilocybin therapy | — | — | — | — | — | 1 | |
| Indocyanine Green | — | — | — | — | — | 1 | |
| [18F]CETO tracer | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| Tiragolumab and atezolizumab | — | — | — | — | — | 1 | |
| Risankizumab-800CW 4.5 mg | — | — | — | — | — | 1 | |
| Risankizumab-800CW 15 mg | — | — | — | — | — | 1 | |
| Risankizumab-800CW 25 mg | — | — | — | — | — | 1 | |
| Risankizumab-800CW optimal dose | — | — | — | — | — | 1 | |
| Avastin | — | — | — | — | — | 1 |
18 more active programs hidden
Next readouts
- 2025-02-06
- 2025-06
- 2025-06-01
- 2025-08
- 2025-09
- 2025-11
- 2025-12
- 2025-12-31
- 2026-03
- 2026-03
Top conditions
- Heart Failure18
- Breast Cancer17
- Melanoma12
- COPD12
- Esophageal Cancer11
- Asthma10
- Critical Illness10
- Cancer10
Frequently asked questions about University Medical Center Groningen
- How many clinical trials does University Medical Center Groningen have on ClinicalTrials.gov?
- University Medical Center Groningen is listed as the lead sponsor on 619 clinical trials in ClinicalTrials.gov, 150 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Medical Center Groningen's trials are in Phase 3?
- 31 of University Medical Center Groningen's trials are in Phase 3, spread across 58 active drug programs.
- What therapeutic areas does University Medical Center Groningen focus on?
- University Medical Center Groningen's most-studied conditions on ClinicalTrials.gov are Heart Failure, Breast Cancer, Melanoma, COPD, Esophageal Cancer.
- When are University Medical Center Groningen's next clinical trial readouts?
- University Medical Center Groningen has 10 upcoming primary-completion readouts tracked here; the soonest is “Investigating Cardiovascular Adverse Events Related to Cancer Treatment”, expected around 2025-02-06.